High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Strong revenue growth driven by Eliquis and key growth assets, offset by Opdivo decline and delayed readouts for Milvexian and Cobenfy.
Bristol Myers Squibb (NYSE:BMY) reported second-quarter results that comfortably exceeded Wall Street expectations, driven by continued strength across its growth portfolio. The pharmaceutical company also raised its full-year 2026 financial outlook, sending its shares more than 1% higher in premarket trading on Thursday.
Strong sales of blood thinner Eliquis and newer drugs Camzyos and Reblozyl pushed second-quarter revenue to $12.97 billion, above analyst estimates
Pfizer heads into Q2 earnings with expectations for growth in key products, COVID headwinds, and guidance updates that could shape its outlook.
BioArctic AB (BRCTF) reports robust financial performance and advances in Alzheimer's treatment, while navigating market access hurdles and rising operational costs.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.